

THERAVANCE INC  
Form 8-K  
July 14, 2008

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **July 14, 2008**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

**000-30319**

(Commission File Number)

**94-3265960**

(I.R.S. Employer Identification Number)

**901 Gateway Boulevard  
South San Francisco, California 94080  
(650) 808-6000**

## Edgar Filing: THERAVANCE INC - Form 8-K

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

*The information contained in this Item 7.01 and in the accompanying exhibits shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.*

On July 14, 2008, Theravance, Inc. (the Company ) issued press releases announcing results from a Phase 2 clinical study ~~in~~ its bifunctional muscarinic antagonist-beta2 agonist (MABA) program and a Phase 1 clinical study in its long-acting muscarinic antagonist (LAMA) program. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 and are incorporated herein by reference. Members of the Company s management will discuss these results and present a slide presentation on a conference call today at 5:00 p.m. Eastern Daylight Time. The slide presentation is available on the Company s website on the bottom left corner under Latest Presentation , and is attached hereto as Exhibit 99.3 and incorporated herein by reference.

**ITEM 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit</b>	<b>Description</b>
Exhibit 99.1	Press release dated July 14, 2008
Exhibit 99.2	Press release dated July 14, 2008
Exhibit 99.3	Slide presentation

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: July 14, 2008

By:

/s/ Rick E Winningham

**Rick E Winningham**  
**Chief Executive Officer**

**EXHIBIT INDEX**

<b>Exhibit No.</b>		<b>Exhibit</b>
99.1	Press release dated July 14, 2008	
99.2	Press release dated July 14, 2008	
99.3	Slide presentation	